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OBJECTIVE—To assess the potential association between A1C variability (A1C-SD) and
microalbuminuria in young people with type 1 diabetes.
RESEARCH DESIGN AND METHODS—Serially collected samples for A1C measure-
ment were available for 1,232 subjects with childhood-onset type 1 diabetes recruited to the
Oxford Regional Prospective Study and the Nephropathy Family Study.
RESULTS—Themedian(range)numberofA1Cassessmentswas4(2–16).Meanintrapersonal
A1Cwas9.5%andA1C-SDwas0.91.MeanA1CandA1C-SDvalueswerehigherinsubjectswith
microalbuminuria (n= 227) than in those with normoalbuminuria (10.3vs. 9.4%; 1.12vs. 0.86,
P , 0.001). In a Cox regression model, A1C-SD was independently associated with microalbu-
minuria (hazard ratio 1.31 [95% CI 1.01–1.35]).
CONCLUSIONS—In the current study, A1C variability was an independent variable that
added to the effect of A1C on the risk for microalbuminuria in youth with type 1 diabetes, a
population highly vulnerable to vascular complications.
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L
andmark studies, such as the Diabe-
tes Control and Complications Trial
(DCCT) and the Epidemiology of
Diabetes and its Complications (EDIC),
showed the importance of good glycemic
control, as expressed by A1C values
within normal reference ranges, in reduc-
ing the risk of vascular complications
(1,2). Recent data from the DCCT and
Finnish Diabetic Nephropathy (FinnDiane)
studyhighlightanadditionalcomponentof
glycemic control, represented by A1C vari-
ability,independentlyassociated withcom-
plication risk in type 1 diabetes (3,4).
A1C variability, expressed as the in-
trapersonal SD of serially measured A1C,
is considered an index of long-term gly-
cemic variability (3–5). Up to now, how-
ever, the relationship between A1C
variability and vascular complications
has not been assessed in young people
with diabetes. It would be of interest to
understand whether this parameter has
an independent role in this group, where
complicationriskcanbeevenhigher than
in adults and is associated with distinct
risk factors such as puberty (6). There-
fore, the aim of this study was to assess
whether A1C variability was associated
with microalbuminuria in young people
with type 1 diabetes.
RESEARCH DESIGN AND
METHODS—The study population
consisted of 1,232 participants in the
Oxford Regional Prospective Study
(ORPS,n=418)andNephropathyFamily
Study (NFS, n = 814) with more than one
A1C assessment, representing 84% of the
whole cohorts. No participants were
receiving treatment with any drug apart
from insulin. Ethical approval was ob-
tained from the district ethics committee,
withwrittenconsentfromtheparentsand
assent from the children.
Between 1986 and 1996, the ORPS
recruited children diagnosed with type 1
diabetes aged ,16 years in the geo-
graphic region of the Oxford Health Au-
thority (7). Between 2000 and 2005, the
NFS recruited adolescents aged 10–16
years with type 1 diabetes throughout
England (8).
Both cohorts have been monitored
with annual assessments of A1C and the
albumin/creatinine ratio (ACR). Microal-
buminuria was deﬁned as an ACR of be-
tween 3.5 and 35 mg/mmol in males and
between 4.0 and 47 mg/mmol in females
in two of three consecutive early morning
urine samples (7,8) and was considered
“persistent” when detected for $2c o n s e c -
utive years or “transient” when present for
1 year with subsequent regression.
All urine samples were assessed cen-
trally, as previously reported (7,8). A1C
from ORPS was analyzed centrally, ini-
tially by an electrophoretic method (Ciba
Corning Diagnostics, Halstead, U.K.) and
then by high-performance liquid chroma-
tography (Bio-Rad, Hemel Hempstead,
U.K.), with DCCT-aligned methods (9).
A1C from NFS was analyzed centrally
on a Tosoh G7 Analyzer (Redditch, U.K.)
using high-performance liquid chroma-
tography and absorbance change detec-
tion and DCCT-aligned methods (8).
Foreachpatient,theintrapersonalSD
for A1C (A1C-SD) was calculated as the
mean of all available A1C measurements
until the age of 25 years. For subjectswith
microalbuminuria, only A1C measure-
mentsbeforetheonsetofthiscomplication
were included. An adjusted SD (adj-A1C-
SD = SD/![n/(n 2 1)]) was calculated to
adjust for a different number of assess-
ments among patients (3).
Data are expressed as mean 6 SD or
median (interquartile range [IQR]). Un-
paired t test and ANOVA with Bonferroni
post hoc test were used for comparisons
between groups. A Cox regression analy-
sis was performed to assess the association
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Analyses were performed using SPSS 16
software (SPSS Inc., Chicago, IL).
RESULTS—The study population in-
cluded 1,232 patients (683 boys;
Supplementary Data). Their median
(IQR) age at diagnosis was 9.2 (5.7–
11.7) years, and diabetes duration at last
A1C assessment was 8.6 (5.6–11.6) years.
These participants were not dissimilar
from the rest of the cohorts for male per-
centage (55%), age at diagnosis (9.6 [6.0–
11.9] years), and duration of diabetes at
the last visit (8.5 [5.5–11.9] years). The
median (range) number of A1C assess-
ments was four (2–16), mean A1C was
9.5% (ORPS: 9.8; NFS: 9.4), A1C-SD
was 1.05 (ORPS: 1.27; NFS: 0.94), and
adj-A1C-SD was 0.91 (ORPS: 1.15; NFS:
0.78).
Mean A1C and adj-A1C-SD were
higher in the227 subjects whodeveloped
microalbuminuria than in those with
normoalbuminuria (10.4 vs. 9.4%; 1.16
vs. 0.86, P , 0.001). Similar differences
were found when the ORPS (A1C: 10.5
vs.9.6%[P,0.001];adj-A1C-SD:1.32vs.
1.10 [P , 0.001]) and NFS (A1C: 10.0
vs. 9.3% [P , 0.001]; adj-A1C-SD: 0.91
vs. 0.76 [P = 0.005]) cohorts were ana-
lyzed separately. After dividing the micro-
albuminuric group in persistent (n = 82)
and transient (n = 145) subgroups, A1C
and adj-A1C-SD were different between
normoalbuminuric versus persistent (9.4
vs.10.7%and0.9vs.1.3[P,0.001])and
transient microalbuminuric (A1C: 10.2%;
adj-A1C-SD: 1.1 [P , 0.001]), but not be-
tween the persistent and transient micro-
albuminuric patients. In a Cox regression
model, adj-A1C-SD was independently as-
sociated with microalbuminuria (Table 1).
CONCLUSIONS—In the current
study, A1C variability was indepen-
dentlyassociatedwithmicroalbuminuria
in young patients with childhood-onset
type 1 diabetes. These results are in line
with those from adult studies, where A1C
variability was associated with nephropa-
thy, retinopathy, and cardiovascular risk
(3–5).
Some have suggested that A1C var-
iability, reﬂecting long-term glycemic
variability, may be linked to vascular com-
plications by increasing oxidative stress
(13). This is supported by the ﬁnding
that glucose ﬂuctuations induce oxidant
production, and this effect appears to be
even stronger than that caused by stable
high-glucose values (10,11). The role of
oxidative stress in the pathogenesis of vas-
cular complications is well known and is
suggested as the ﬁnal mediator of several
hyperglycemia-activated pathways (12).
However,theassociationbetweenA1Cvar-
iability and vascular complications might
be explained by other unknown mecha-
nisms, which needtobeexplored infuture
studies.
These results highlight the concept
that a good, stable glycemic control is of
paramount importance and must be es-
tablished early in the course of diabetes.
RecentupdateddatafromtheEDICstudy
showed that the so-claimed metabolic
memory, expression of earlier glycemic
control, can wear off in the long-term,
particularly in young people, and glyce-
mic control during the earlier DCCT was
the main determinant of this phenome-
non (13). Therefore, young people with
diabetes should be strongly encouraged
to achieve a good glycemic control, to
keep it over time, and to avoid even short
periods of hyperglycemia.
A main strength of this study is the
l a r g es a m p l es i z ea n dt h ep r o s p e c t i v e
design, which allowed the availability
of a large number of samples for A1C
assessment. Another strength is the central
assessment of all A1C assays. In contrast, a
potential limitation was the use of different
methods to assess A1C in the two cohorts.
Further studies in youth with type 1
diabetes would likely replicate the results
of this study and extend the investigation
to other complications of diabetes.
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